BR112013001637A2 - proteína ligadora de antígeno, molécula de ácido nucleico, vetor de expressão, célula hospedeira recombinante, métodos para produção de proteína ligadora de antígeno, e para detectar mage-a3 e/ou mage-a6 em tecido de humano fixado com formalina e infiltrado em parafina. - Google Patents

proteína ligadora de antígeno, molécula de ácido nucleico, vetor de expressão, célula hospedeira recombinante, métodos para produção de proteína ligadora de antígeno, e para detectar mage-a3 e/ou mage-a6 em tecido de humano fixado com formalina e infiltrado em parafina.

Info

Publication number
BR112013001637A2
BR112013001637A2 BR112013001637A BR112013001637A BR112013001637A2 BR 112013001637 A2 BR112013001637 A2 BR 112013001637A2 BR 112013001637 A BR112013001637 A BR 112013001637A BR 112013001637 A BR112013001637 A BR 112013001637A BR 112013001637 A2 BR112013001637 A2 BR 112013001637A2
Authority
BR
Brazil
Prior art keywords
mage
antigen
binding protein
methods
formalin
Prior art date
Application number
BR112013001637A
Other languages
English (en)
Inventor
Alain Bergeron
Anthony Pilorget
Normand Blais
Remi M Palmanrier
Yves Fradet
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of BR112013001637A2 publication Critical patent/BR112013001637A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

proteína ligadora de antígeno, molécula de ácido nucleico, vetor de expressão, célula hospedeira recombinante, métodos para a produção de proteína ligadora de antígeno, e para detectar mage-a3 e/ou mage-a6 em tecido de humano fixado com formalina e infiltrado em parafina - a presente invenção refere-se às proteínas ligadoras de antígeno, que se ligam em mage-3, aos polinucleotídeos codificados de tais proteínas ligadoras de antígeno, às aplicações diagnósticas de ditas proteínas ligadoras de antígeno e aos métodos de manufatura.
BR112013001637A 2010-07-22 2011-07-20 proteína ligadora de antígeno, molécula de ácido nucleico, vetor de expressão, célula hospedeira recombinante, métodos para produção de proteína ligadora de antígeno, e para detectar mage-a3 e/ou mage-a6 em tecido de humano fixado com formalina e infiltrado em parafina. BR112013001637A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36674210P 2010-07-22 2010-07-22
PCT/EP2011/062458 WO2012010635A1 (en) 2010-07-22 2011-07-20 Novel antigen binding proteins

Publications (1)

Publication Number Publication Date
BR112013001637A2 true BR112013001637A2 (pt) 2016-05-24

Family

ID=44628731

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013001637A BR112013001637A2 (pt) 2010-07-22 2011-07-20 proteína ligadora de antígeno, molécula de ácido nucleico, vetor de expressão, célula hospedeira recombinante, métodos para produção de proteína ligadora de antígeno, e para detectar mage-a3 e/ou mage-a6 em tecido de humano fixado com formalina e infiltrado em parafina.

Country Status (7)

Country Link
US (1) US8987423B2 (pt)
EP (1) EP2596027A1 (pt)
JP (1) JP5883443B2 (pt)
CN (1) CN103108887A (pt)
BR (1) BR112013001637A2 (pt)
CA (1) CA2805035A1 (pt)
WO (1) WO2012010635A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014013806A (es) * 2012-05-14 2014-11-26 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores.
GB201315946D0 (en) * 2013-09-06 2013-10-23 Immune Targeting Systems Its Ltd Oncology vaccine
CN106397587A (zh) * 2016-06-24 2017-02-15 安徽未名细胞治疗有限公司 一种全人源抗MAGEA3的全分子IgG抗体及其应用
WO2018097951A1 (en) * 2016-11-22 2018-05-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mage-a3/a6 antibodies
WO2019007974A1 (en) 2017-07-07 2019-01-10 Immatics Biotechnologies Gmbh NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF LUNG CANCER, INCLUDING NSCLC, CPPC AND OTHER CANCERS
TW201906859A (zh) 2017-07-07 2019-02-16 德商英麥提克生物技術股份有限公司 用於肺癌（包括 nsclc、sclc 和其他癌症）免疫治療的新型肽和肽組合物
WO2021173674A1 (en) * 2020-02-26 2021-09-02 A2 Biotherapeutics, Inc. Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5795737A (en) 1994-09-19 1998-08-18 The General Hospital Corporation High level expression of proteins
DE69836206T2 (de) 1997-02-07 2007-08-23 Merck & Co., Inc. Synthetische hiv gag gene
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
GB0612342D0 (en) * 2006-06-21 2006-08-02 Glaxosmithkline Biolog Sa Method
ES2304306B1 (es) * 2007-03-20 2009-07-07 Indas Biotech, S.L.U. Metodo de diagnostico y/o pronostico de cancer vesical.
WO2011066265A1 (en) * 2009-11-25 2011-06-03 Ludwig Institute For Cancer Research Ltd. Cancer testis antigens as biomarkers in non-small cell lung cancer

Also Published As

Publication number Publication date
JP5883443B2 (ja) 2016-03-15
US20130123472A1 (en) 2013-05-16
JP2013538557A (ja) 2013-10-17
CN103108887A (zh) 2013-05-15
CA2805035A1 (en) 2012-01-26
EP2596027A1 (en) 2013-05-29
US8987423B2 (en) 2015-03-24
WO2012010635A1 (en) 2012-01-26

Similar Documents

Publication Publication Date Title
BR112013001637A2 (pt) proteína ligadora de antígeno, molécula de ácido nucleico, vetor de expressão, célula hospedeira recombinante, métodos para produção de proteína ligadora de antígeno, e para detectar mage-a3 e/ou mage-a6 em tecido de humano fixado com formalina e infiltrado em parafina.
MX353382B (es) Moleculas de union polipeptido de larga duracion.
PH12015501651A1 (en) Antibody constructs for cdh19 and cd3
MX2015008446A (es) Composiciones de proteinas de union multivalentes.
BR112017012910A2 (pt) proteína de fusão que compreende três domínios de ligação a 5t4 e cd3
UY35456A (es) Moléculas de unión para bcma y cd3
BR112014011331A2 (pt) anticorpos específicos para trop-2 e seus usos
BR112012029588A2 (pt) materiais biológicas relacionados a her3.
AR090047A1 (es) Dominio variable dual de inmunoglobulinas y sus usos
BR112013005699A2 (pt) moléculas de ligação a 4-1bb
CL2012002783A1 (es) Proteinas de unión humanizada que se une al factor de necrosis tumoral alfa humano (tnf-alfa); composicion para liberar una proteina que se une a tnf-alfa; construccionde una proteina que puede unirse al tnf-alfa; acido nucleico, vector y celula huesped que comprenden dicha construccion.
MX2011009897A (es) Anticuerpo de antagonista especifico de heterodimero alfa-4-beta-7.
BR112013020338A2 (pt) proteína de ligação de antígeno monovalente, composição farmacêutica, uso da proteína de ligação de antígeno monovalente, método para o tratamento de um paciente com necessidade de terapia, método para a preparação de uma proteína de ligação de antígeno monovalente, ácido nucleico, vetor e célula hospedeira
BR112012020705A2 (pt) axmi221z, axmi222z, axmi224z, e axmi225z genes de delta-endotoxina e métodos para sua utilização.
WO2011079902A3 (en) Biological inhibitors of ror1 capable of inducing cell death
EA201300311A1 (ru) Vegf-связывающие молекулы
CL2009000862A1 (es) Anticuerpo aislado, derivados o fragmentos aislados del mismo capaz de unirse a la proteina cd151, composición que lo comprende; ácido nucleico que lo codifica, vector y célula huesped que lo comprenden; procedimiento para preparar dicho anticuerpo; util como medicamento para prevenir o tratar el cáncer.
BR112013008255A2 (pt) anticorpo isolado ou um fragmento funcional do mesmo, uso de um anticorpo isolado ou de um fragmento funcional do mesmo, composição farmacêutica, polinucleotídeo, vetor, célula transformada, e, método para produzir anticorpo
BR112017022255A2 (pt) anticorpo humanizado ou humano isolado, molécula de ácido nucleico isolada, vetor, célula hospedeira, método para produzir um anticorpo, e composição farmacêutica
BR112015003724A2 (pt) polipeptídeo isolado, composição, uso de uma composição, polinucleotídeo isolado, constructo de ácido nucleico ou vetor de expressão, célula hospedeira recombinante, e, métodos de produção de um polipeptídeo e de produção de uma proteína.
BR112015013387A2 (pt) proteínas tipo espiral enrolada modificadas possuindo propriedades melhoradas
BR112016024462A2 (pt) ?métodos para a preparação de uma proteína, proteína heteromultimérica, composição e célula hospedeira?
BR112014023063A2 (pt) anticorpos que neutralizam rsv, mpv e pvm e usos dos mesmos
BR112021017860A2 (pt) Anticorpo ou fragmento de anticorpo isolado específico para c5ar de humano, composição de ácido nucleico, composição de vetor, célula hospedeira e composição farmacêutica
BR112013031590A2 (pt) compostos de ligação ao adrenorreceptor beta1 humano (beta1-ar) e seu uso na medida de anticorpos auto-anti-beta1-ar

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]